174 related articles for article (PubMed ID: 32321347)
21. Clinical evaluation of [
Schmidt ME; Janssens L; Moechars D; Rombouts FJR; Timmers M; Barret O; Constantinescu CC; Madonia J; Russell DS; Sandiego CM; Kolb H
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3176-3185. PubMed ID: 32535652
[TBL] [Abstract][Full Text] [Related]
22. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls.
Newberg AB; Arnold SE; Wintering N; Rovner BW; Alavi A
J Nucl Med; 2012 Jun; 53(6):902-7. PubMed ID: 22577238
[TBL] [Abstract][Full Text] [Related]
23. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
[TBL] [Abstract][Full Text] [Related]
24. Quantification of SV2A Binding in Rodent Brain Using [
Sadasivam P; Fang XT; Toyonaga T; Lee S; Xu Y; Zheng MQ; Spurrier J; Huang Y; Strittmatter SM; Carson RE; Cai Z
Mol Imaging Biol; 2021 Jun; 23(3):372-381. PubMed ID: 33258040
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of
Bullich S; Barret O; Constantinescu C; Sandiego C; Mueller A; Berndt M; Papin C; Perrotin A; Koglin N; Kroth H; Pfeifer A; Tamagnan G; Madonia J; Seibyl JP; Marek K; De Santi S; Dinkelborg LM; Stephens AW
J Nucl Med; 2020 Jun; 61(6):920-927. PubMed ID: 31712324
[No Abstract] [Full Text] [Related]
27. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
Lister-James J; Pontecorvo MJ; Clark C; Joshi AD; Mintun MA; Zhang W; Lim N; Zhuang Z; Golding G; Choi SR; Benedum TE; Kennedy P; Hefti F; Carpenter AP; Kung HF; Skovronsky DM
Semin Nucl Med; 2011 Jul; 41(4):300-4. PubMed ID: 21624563
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [
Guehl NJ; Wooten DW; Yokell DL; Moon SH; Dhaynaut M; Katz S; Moody KA; Gharagouzloo C; Kas A; Johnson KA; El Fakhri G; Normandin MD
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2099-2111. PubMed ID: 31332496
[TBL] [Abstract][Full Text] [Related]
29. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
Camus V; Payoux P; Barré L; Desgranges B; Voisin T; Tauber C; La Joie R; Tafani M; Hommet C; Chételat G; Mondon K; de La Sayette V; Cottier JP; Beaufils E; Ribeiro MJ; Gissot V; Vierron E; Vercouillie J; Vellas B; Eustache F; Guilloteau D
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):621-31. PubMed ID: 22252372
[TBL] [Abstract][Full Text] [Related]
30. Validation of the Semiquantitative Static SUVR Method for
Ottoy J; Verhaeghe J; Niemantsverdriet E; Wyffels L; Somers C; De Roeck E; Struyfs H; Soetewey F; Deleye S; Van den Bossche T; Van Mossevelde S; Ceyssens S; Versijpt J; Stroobants S; Engelborghs S; Staelens S
J Nucl Med; 2017 Sep; 58(9):1483-1489. PubMed ID: 28336779
[TBL] [Abstract][Full Text] [Related]
31. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
[TBL] [Abstract][Full Text] [Related]
32. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
33. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic Evaluation of the Tau PET Radiotracer
Wooten DW; Guehl NJ; Verwer EE; Shoup TM; Yokell DL; Zubcevik N; Vasdev N; Zafonte RD; Johnson KA; El Fakhri G; Normandin MD
J Nucl Med; 2017 Mar; 58(3):484-491. PubMed ID: 27660144
[No Abstract] [Full Text] [Related]
35. Optimisation and usefulness of quantitative analysis of
Fakhry-Darian D; Patel NH; Khan S; Barwick T; Svensson W; Khan S; Perry RJ; Malhotra P; Carswell CJ; Nijran KS; Win Z
Br J Radiol; 2019 Sep; 92(1101):20181020. PubMed ID: 31017465
[TBL] [Abstract][Full Text] [Related]
36. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.
Siderowf A; Pontecorvo MJ; Shill HA; Mintun MA; Arora A; Joshi AD; Lu M; Adler CH; Galasko D; Liebsack C; Skovronsky DM; Sabbagh MN
BMC Neurol; 2014 Apr; 14():79. PubMed ID: 24716655
[TBL] [Abstract][Full Text] [Related]
37. In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand
Betthauser TJ; Cody KA; Zammit MD; Murali D; Converse AK; Barnhart TE; Stone CK; Rowley HA; Johnson SC; Christian BT
J Nucl Med; 2019 Jan; 60(1):93-99. PubMed ID: 29777006
[TBL] [Abstract][Full Text] [Related]
38. Kinetics and 28-day test-retest repeatability and reproducibility of [
Tuncel H; Boellaard R; Coomans EM; de Vries EF; Glaudemans AW; Feltes PK; García DV; Verfaillie SC; Wolters EE; Sweeney SP; Ryan JM; Ivarsson M; Lynch BA; Schober P; Scheltens P; Schuit RC; Windhorst AD; De Deyn PP; van Berckel BN; Golla SS
J Cereb Blood Flow Metab; 2021 Jun; 41(6):1338-1350. PubMed ID: 34013797
[TBL] [Abstract][Full Text] [Related]
39. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study.
Planton M; Saint-Aubert L; Raposo N; Payoux P; Salabert AS; Albucher JF; Olivot JM; Péran P; Pariente J
J Alzheimers Dis; 2020; 73(4):1607-1614. PubMed ID: 31958082
[TBL] [Abstract][Full Text] [Related]
40. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.
Lopresti BJ; Klunk WE; Mathis CA; Hoge JA; Ziolko SK; Lu X; Meltzer CC; Schimmel K; Tsopelas ND; DeKosky ST; Price JC
J Nucl Med; 2005 Dec; 46(12):1959-72. PubMed ID: 16330558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
